Intellia Therapeutics, Inc. (NTLA) Stock Price & How to Invest

Intellia Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts, developing genome-editing therapies based on CRISPR/Cas9. Its core differentiator is a proprietary in vivo platform that delivers the editing machinery directly into the body, typically the liver, using lipid nanoparticles, so that a single dose can permanently inactivate or modify a disease-causing gene without removing cells from the patient. This contrasts with ex vivo approaches that edit cells outside the body and reinfuse them. The company is pre-revenue from products and currently records only collaboration revenue from partners; it funds operations through its cash reserves and periodic capital raises.

Intellia was co-founded in 2014, drawing on foundational CRISPR research associated with Nobel laureate Jennifer Doudna, and went public on the Nasdaq in 2016. Its two most advanced wholly described programs are lonvoguran ziclumeran (lonvo-z, formerly NTLA-2002) for hereditary angioedema and nexiguran ziclumeran (nex-z, formerly NTLA-2001) for transthyretin (ATTR) amyloidosis, the latter developed in collaboration with Regeneron Pharmaceuticals. In 2025 the company prioritized these late-stage assets through a strategic reorganization. As of mid-2026, lonvo-z had reported positive Phase 3 HAELO results and entered rolling FDA biologics license application review, while the nex-z Phase 3 MAGNITUDE and MAGNITUDE-2 trials in ATTR were advancing after the FDA lifted earlier clinical holds.

Intellia is pre-revenue from products, deeply unprofitable, and its value depends on binary clinical and regulatory outcomes; a single failed trial, safety signal, or FDA setback for lonvo-z or nex-z could sharply reduce the stock's value. The company burns roughly $90 million to $100 million per quarter and has repeatedly raised equity to extend its runway, so existing shareholders face ongoing dilution risk before any product profit materializes. Even with positive data, regulatory approval, reimbursement, and commercial adoption of a novel one-time gene-editing therapy are uncertain and could take years. The company also competes with better-capitalized CRISPR and gene-editing peers, with RNA-interference and stabilizer drugs already approved in ATTR, and with established prophylaxis options in hereditary angioedema.

17 analysts publish price targets on NTLA, averaging $25.94 against a $10.68 price as of August 2026, or +142.9%. The published targets run from $8.00 to $95.00, a wide spread, and the ratings split 9 buy, 7 hold, 3 sell. Over the last six months there have been 4 raises and 2 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full NTLA forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Intellia Therapeutics, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Positive Late-Stage Lonvo-z Data in Hereditary Angioedema. In 2026 Intellia reported positive Phase 3 HAELO results for lonvo-z in hereditary angioedema, including an approximately 87 percent reduction in mean monthly attacks versus placebo, with a majority of treated patients reported as attack-free over the efficacy period. The most optimistic published target, $95.00, assumes this works close to its best case.

The case against. Intellia is pre-revenue from products, deeply unprofitable, and its value depends on binary clinical and regulatory outcomes; a single failed trial, safety signal, or FDA setback for lonvo-z or nex-z could sharply reduce the stock's value. The most pessimistic target, $8.00, is roughly what NTLA is worth if this bites instead.

Read the full bull and bear case on NTLA, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Intellia Therapeutics, Inc.'s investor relations page or your broker.

• Cash and Marketable Securities: ~$517 million (as of March 31, 2026), plus ~$207 million gross from an April 2026 equity offering
• Stated Cash Runway: Expected to fund operations at least into 2028
• Net Loss (Q1 2026): ~$96 million (versus ~$114 million in Q1 2025)
• Revenue: Collaboration revenue only (e.g., Regeneron); no product revenue yet
• Market Capitalization: ~$1.7 billion (June 2026, moves sharply on clinical news)
• P/E Ratio (TTM): Negative (not meaningful; company is unprofitable)

Because Intellia has no product profits and only collaboration revenue, traditional earnings-based valuation multiples like P/E are negative and not analytically useful. The stock is better evaluated on its cash runway relative to its burn rate, the probability and timing of regulatory approval for lonvo-z and nex-z, and the risk-adjusted commercial potential of those programs. The April 2026 equity raise extended the stated runway at least into 2028, but pre-profit biotechs of this type typically require additional capital before reaching sustained profitability, so dilution and the binary nature of trial readouts are central to any valuation view.

If you want NTLA exposure as part of a larger bundle rather than directly, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

These are the investment theses NTLA naturally fits into. Each links to a full theme guide listing every other stock that belongs and the ETFs commonly used as a passive proxy.

Other names that sit close to NTLA: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get NTLA exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (ARKG), which spreads the position across many companies. Or build it into a focused thematic portfolio, so NTLA sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where NTLA fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Intellia Therapeutics is a pre-commercial gene-editing company whose value is concentrated in a small number of late-stage programs that have not yet reached the market. If you believe in vivo CRISPR editing will become a durable treatment modality and that lonvo-z and nex-z can clear regulatory review and launch successfully over the next few years, the relevant questions become position sizing and overlap with other speculative biotech holdings, not timing. The opposing case is that any single clinical setback, regulatory delay, or safety signal could sharply reduce the stock's value, and that continued cash burn means shareholders face ongoing dilution risk before the company ever earns a profit.

Whether NTLA is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is NTLA a buy or a sell?, and where the stock could go from here in the NTLA stock forecast.

For income investors, whether NTLA pays a dividend and how the payout looks is covered in does NTLA pay a dividend? And to weigh NTLA against a peer, read the full side-by-side comparisons: NTLA vs BEAM and NTLA vs CRSP.